Atlas Trials

NuGenerex Immuno-Oncology

1 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch NuGenerex Immuno-Oncology

RecordFirmDate
Establishing the Recommended Biological Dose for AE37 Peptide Vaccine in Combination With Pembrolizumab That Will Enhance the Tumor-specific Immune Response and Demonstrate Efficacy in Patients With Advanced Triple-negative Breast Cancer (NCT04024800)NuGenerex Immuno-Oncology2019-05-03

Track NuGenerex Immuno-Oncology automatically

Every clearance here is in the API, with alerts when new ones post.